Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Introduction: Blood-based colorectal cancer (CRC) screening has entered clinical practice with FDA approval of SimpleScreen CRC, a plasma cell-free DNA test for average-risk adults aged ≥45 years. The...
Introduction: Choosing treatment for ampullary tumours requires balancing oncological completeness against procedural morbidity. Endoscopic resection (ER) is increasingly used for benign lesions; transduodenal ampullectomy (TDA) offers a surgical...
Introduction: With three major multidrug regimens available for frontline metastatic pancreatic ductal adenocarcinoma (PDAC), treatment selection has become increasingly nuanced. NALIRIFOX has joined FOLFIRINOX and gemcitabine–nab-paclitaxel as an...
Introduction: Patients with unresectable, non-metastatic distal cholangiocarcinoma (dCCA) have limited locoregional treatment options. The FDA has granted a Humanitarian Device Exemption (HDE) to OncoSil, an EUS-delivered intratumoral radiation...
Introduction: For RAS wild-type, left-sided metastatic colorectal cancer (mCRC), chemotherapy plus anti-EGFR therapy is an established first-line strategy. Whether intensifying the chemotherapy backbone to mFOLFOXIRI adds meaningful long-term...
Introduction: Adjuvant imatinib has clearly improved recurrence-free survival after complete resection of high-risk gastrointestinal stromal tumours (GISTs). However, important questions remain regarding who truly benefits, optimal treatment duration,...
Introduction: Early-onset colorectal cancer (EOCRC) is rising globally and increasingly appears to be biologically distinct from conventional later-onset CRC. This large clinicogenomic analysis evaluated 6,762 tumors across four...
Introduction: Adjuvant imatinib has clearly improved recurrence-free survival after complete resection of high-risk gastrointestinal stromal tumors (GISTs). However, important questions remain regarding who truly benefits, optimal treatment duration,...
Introduction: Radioligand therapy is becoming increasingly important in somatostatin receptor–positive neuroendocrine tumors. The FDA has issued a Complete Response Letter (CRL) for ¹⁷⁷Lu-edotreotide (ITM-11) in advanced GEP-NETs. Importantly,...
Introduction: Despite neoadjuvant chemotherapy and curative resection, 40–60% of patients with locally advanced oesophagal squamous cell carcinoma (ESCC) ultimately develop recurrence. Conventional imaging and pathological response assessment may...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.